Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Purselle

Psychiatry Atlanta, GA Medical Doctor

NPI 1356384135 CMS profile 715381

652 Bellemeade Ave Nw, Atlanta, GA 30318

Open in the dashboard

General payments

$307,271

726 records reported · program years 2019–2025

Research payments

$1,853

Paid to them · 10 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,063,998 paid to institutions, not to them · program years 2019–2025

Through program year 2025, David Purselle of Atlanta, GA is reported in the CMS Open Payments database as having received $307,271 across 726 general payments and $1,853 in research payments paid to them. Separately, studies naming them as principal investigator received $7,063,998 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $80,699 132
2024 General $57,152 133
2023 General $91,827 169
2022 General $56,227 112
2021 General $7,325 73
2020 General $5,075 61
2019 General $8,967 46
2019 Research $1,853 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Purselle
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to David Purselle were reported at $80,699. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year David Purselle Psychiatry median Middle half National median
2019 $8,967 $184 $59–$605 $163
2020 $5,075 $119 $36–$372 $114
2021 $7,325 $143 $43–$576 $132
2022 $56,227 $153 $50–$590 $149
2023 $91,827 $170 $56–$651 $160
2024 $57,152 $179 $57–$673 $164
2025 $80,699 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $107,922 165 payments
  2. Supernus Pharmaceuticals, Inc. $62,010 112 payments
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. $59,701 61 payments
  4. Axsome Therapeutics, Inc. $21,542 17 payments
  5. Brainsway USA Inc $15,893 6 payments
  6. Vanda Pharmaceuticals Inc. $11,598 38 payments
  7. Janssen Pharmaceuticals, Inc $8,626 26 payments
  8. Idorsia Pharmaceuticals US Inc $6,595 7 payments
  9. Otsuka America Pharmaceutical, Inc. $5,268 46 payments
  10. Neurocrine Biosciences, Inc. $2,151 13 payments
  11. Other $5,965 235 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $196,142 76 payments
  2. Consulting Fee $72,272 14 payments
  3. Travel and Lodging $22,974 111 payments
  4. Food and Beverage $13,033 520 payments
  5. Honoraria $2,750 1 payment
  6. Education $100 4 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $95,281 147 payments
  2. REXULTI $55,229 91 payments
  3. QELBREE Psychology $37,998 69 payments
  4. Qelbree Viloxazine Hydrochloride $24,012 43 payments
  5. Auvelity $21,542 17 payments
  6. BrainsWay Deep TMS $15,854 4 payments
  7. VRAYLAR Neuroscience $12,866 40 payments
  8. FANAPT $11,598 38 payments
  9. SPRAVATO $8,595 24 payments
  10. QUVIVIQ $6,595 7 payments
  11. Other $5,947 265 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,853 10 payments

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

126

Median for Psychiatry: 574

Drug cost

$11,332

Median for Psychiatry: $27,624

Branded share of claims

24.6%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trintellix Vortioxetine Hydrobromide Brand 16 $10,330
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 15 $279
Trazodone Hcl Generic 17 $264
Quetiapine Fumarate Generic 17 $249
Clonazepam Generic 34 $127
Alprazolam Generic 27 $83

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
$24,012 — —
VRAYLAR
$18,664 — —
Auvelity
$12,010 — —
CAPLYTA
$226 — —
REXULTI
$175 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

736 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record